Wenzel M, Ruvolo CC, Würnschimmel C, et al. - Overall survival (OS) and cancer-specific survival (CSS) of elderly men with newly diagnosed metastatic prostate cancer (mPCa) were not altered by external beam radiation therapy (EBRT). Therefore, the added value of local EBRT in this patient population is questioned.

• Using Surveillance, Epidemiology and End Results (2004–2016), elderly newly diagnosed mPCa patients, aged >75 years, (n=6556) were included; EBRT was administered to 1105 patients.

• EBRT resulted in a median OS of 23 months, vs 23 months for no EBRT (hazard ratio [HR]: 0.97).

• With EBRT, median CSS was 29 months, it was 30 months for no EBRT (HR: 1.04).

• Following additional multivariable adjustment, EBRT was not related to lower overall mortality or lower cancer-specific mortality in the whole cohort, as well as post-stratification for M1b and M1c substages.